Skip to content
2000

A Randomized Trial of Hydroxychloroquine as Post-exposure Prophylaxis for COVID-19

image of A Randomized Trial of Hydroxychloroquine as Post-exposure Prophylaxis for COVID-19

Research revealed that in vitro activity ofchloroquine and the derivative molecule of hydroxychloroquine is against the infection caused by the SARS-CoV and SARS-CoV-2. The US FDA approved the use of both hydroxychloroquinesulfate and chloroquine phosphate for the critical patients of COVID-19. The clinical trials supported that the hydroxychloroquine did not substantially reduce the system severity in non-hospitalized persons. Moreover, it also produces severe side effects like drowsiness, hypokalaemia, nausea, convulsions, shock, and even death.

/content/books/9789815050325.chap7
dcterms_subject,pub_keyword
-contentType:Journal
10
5
Chapter
content/books/9789815050325
Book
false
en
Loading
This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test